In support of this, Kaplan-Meier analysis of overall survival showed that patients whose tumors had higher HSPA2 expression tend to have a significantly worse overall survival, indicating that a high HSPA2 level is a marker of poor prognosis for patients with pancreatic cancer. This evidence concerns the gene HSPA2 and familial pancreatic carcinoma.